{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:21:08Z","timestamp":1789438868559,"version":"build-2803163510"},"reference-count":19,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>With the ongoing emergence of SARS-CoV-2 variants, continued surveillance of antiviral susceptibility remains critical for detecting resistance that could compromise treatment efficacy. This study evaluated the activity of 2 SARS-CoV-2 RNA-dependent RNA polymerase (Nsp12) inhibitors against emerging Omicron variants: remdesivir (RDV), an approved antiviral for the treatment of COVID-19, and obeldesivir (ODV), an oral prodrug that shares the same parent nucleoside as RDV. Both RDV and ODV were shown to retain antiviral activity against the Omicron subvariants BA.2.86.1, JN.1.7, KP.2, KP.3.1.1, KP.3.3, LP.8.1, NB.1.8.1, XBB.2, XEC, and XFG compared with wild-type reference strains. Only 1 new lineage-defining Nsp12 substitution, D284Y (detected in NB.1.8.1), was observed. Phenotypic analysis demonstrated that a replicon containing this substitution remained susceptible to both RDV and ODV. These findings are consistent with previous studies showing that RDV and ODV retain potent activity against previously identified Omicron variants, support the continued clinical use of RDV against circulating SARS-CoV-2 variants, and reinforce the potential of ODV as an oral antiviral therapeutic.<\/jats:p>","DOI":"10.3390\/v18020255","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:50:30Z","timestamp":1771401030000},"page":"255","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025"],"prefix":"10.3390","volume":"18","author":[{"given":"Lauren","family":"Rodriguez","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Li","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Han","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Peinovich","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Martinez","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0728-4352","authenticated-orcid":false,"given":"Pui Yan","family":"Ho","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3000-817X","authenticated-orcid":false,"given":"J. Lizbeth Reyes","family":"Zamora","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-1727","authenticated-orcid":false,"given":"John P.","family":"Bilello","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Perry","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hedskog","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"ref_1","unstructured":"(2026, January 29). WHO COVID-19 Dashboard. Available online: https:\/\/data.who.int\/dashboards\/covid19\/summary?n=o."},{"key":"ref_2","unstructured":"(2025, September 16). COVID-19 Global Risk Assessment. Available online: https:\/\/www.who.int\/publications\/m\/item\/covid-19-global-risk-assessment-v8."},{"key":"ref_3","unstructured":"(2026, January 29). Coronavirus Disease (COVID-19) Epidemiological Updates and Monthly Operational Updates. Available online: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports."},{"key":"ref_4","unstructured":"Gilead Sciences, Inc (2025). VEKLURY\u00ae (Remdesivir) for Injection, for Intravenous Use [Package Insert], Gilead Sciences, Inc.. Available online: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/covid-19\/veklury\/veklury_pi.pdf."},{"key":"ref_5","unstructured":"(2025, November 04). FDA Approves First Treatment for COVID-19, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19."},{"key":"ref_6","unstructured":"(2025, July 17). Veklury European Public Assessment Report-Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/veklury."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11701","DOI":"10.1021\/acs.jmedchem.3c00750","article-title":"Discovery of GS-5245 (obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected African green monkeys","volume":"66","author":"Mackman","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S1473-3099(25)00238-5","article-title":"Efficacy and safety of obeldesivir in low-risk nonhospitalised patients with COVID-19 (OAKTREE): A phase 3, randomised, double-blind, placebo-controlled study","volume":"25","author":"Ogbuagu","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/cid\/ciaf406","article-title":"Efficacy and safety of obeldesivir in high-risk nonhospitalized patients with COVID-19 (BIRCH): A phase 3, randomized, double-blind, placebo-controlled study","volume":"82","author":"Castagna","year":"2026","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rodriguez, L., Zamora, J.L.R., Han, D., Moshiri, J., Peinovich, N., Martinez, C., Ho, P.Y., Li, J., Aeschbacher, T., and Martin, R. (2025). Remdesivir and obeldesivir retain potent antiviral activity against SARS-CoV-2 Omicron variants. Viruses, 17.","DOI":"10.3390\/v17020168"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e0022222","DOI":"10.1128\/aac.00222-22","article-title":"Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants","volume":"66","author":"Pitts","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104974","DOI":"10.1016\/j.antiviral.2020.104974","article-title":"A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2","volume":"185","author":"Zhang","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/infdis\/jiad270","article-title":"Viral resistance analyses from the remdesivir phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)","volume":"228","author":"Hedskog","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hedskog, C., Spinner, C.D., Protzer, U., Hoffmann, D., Ko, C., Gottlieb, R.L., Askar, M., Roestenberg, M., de Vries, J.J.C., and Carbo, E.C. (2024). No remdesivir resistance observed in the phase 3 severe and moderate COVID-19 SIMPLE trials. Viruses, 16.","DOI":"10.3390\/v16040546"},{"key":"ref_15","unstructured":"Han, D., Du Pont, V., Xu, S., Vijjapurapu, A., Li, J., Parhy, B., Martin, R., Camus, G., Perry, J.K., and Porter, D.P. (2023, January 19\u201322). SARS-CoV-2 replicon system for the phenotypic evaluation of Nsp gene substitutions. Proceedings of the CROI 2023, Seattle, WA, USA. Available online: https:\/\/www.croiconference.org\/wp-content\/uploads\/sites\/2\/posters\/2023\/GMI-REV-75400_CROI_2023_poster_FINAL-133208803555392989.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.cell.2020.07.033","article-title":"Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex","volume":"182","author":"Chen","year":"2020","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41586-022-05664-3","article-title":"Structural basis for substrate selection by the SARS-CoV-2 replicase","volume":"614","author":"Malone","year":"2023","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3201\/eid3108.250451","article-title":"Estimated COVID-19 periodicity and correlation with SARS-CoV-2 spike protein S1 antigenic diversity, United States","volume":"31","author":"Rose","year":"2025","journal-title":"Emerg. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12967-020-02344-6","article-title":"Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant","volume":"18","author":"Pachetti","year":"2020","journal-title":"J. Transl. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/255\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:10:33Z","timestamp":1771564233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["v18020255"],"URL":"https:\/\/doi.org\/10.3390\/v18020255","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}